Phase 3 Clinical Trials With Primary Completion Dates in October 2018
This is a list of Phase 3 trials with primary completion dates in October 2018 for companies with a market cap less than $1B. For complete clinical trial coverage, please see our Trial Tracker tool. It includes information on all clinical trials for publicly traded companies, screenable by stock symbol, market cap, disease, completion date, and phase.
The primary completion date is the date that the final subject was examined or received an intervention for the purposes of final collection of data for the primary outcome. It provides advance notice that a company will be announcing trial results in the near future.
| Symbol | Company | Primary Completion Date | Phase | NCT ID | Title |
|---|---|---|---|---|---|
| AMAG | AMAG Pharmaceuticals, Inc. | 2018-10-01 | Phase 3 | NCT01004029 | Confirmatory Study of 17P Versus Vehicle for the Prevention of Preterm Birth in Women With a Previous Singleton Spontaneous Preterm Delivery |
| CHMA | Chiasma, Inc. | 2018-10-01 | Phase 3 | NCT02685709 | Comparison of Oral Octreotide Capsules to Injectable Somatostatin Analogs in Acromegaly |
| MNK | Mallinckrodt plc | 2018-10-01 | Phase 3 | NCT02132195 | Adrenocorticotropic Hormone (ACTH) for Frequently Relapsing and Steroid Dependent Nephrotic Syndrome |
| REPH | Recro Pharma, Inc. | 2018-10-01 | Phase 3 | NCT03434275 | Evaluation of Preoperative N1539 in Total Knee Arthroplasty |
| SPPI | Spectrum Pharmaceuticals, Inc. | 2018-10-01 | Phase 3 | NCT02643420 | RAnDomized Trial of SPI-2012 Versus Pegfilgrastim in the Management of Chemotherapy Induced Neutropenia in Breast CANCEr Patients Receiving Docetaxel and Cyclophosphamide |
| SUPN | Supernus Pharmaceuticals, Inc. | 2018-10-01 | Phase 3 | NCT03247543 | Evaluation of SPN-812 ER High Dose in Children With ADHD |
| VBIV | VBI Vaccines, Inc. | 2018-10-01 | Phase 3 | NCT03393754 | Immunogenicity and Safety of Sci-B-Vac⢠to Engerix-B® in Adults ⥠18 Years Old and Superiority in Adults ⥠45 Years Old. |
| ZGNX | Zogenix, Inc. | 2018-10-01 | Phase 3 | NCT02682927 | A Trial of Two Fixed Doses of ZX008 (Fenfluramine HCl) in Children and Young Adults With Dravet Syndrome |